Regarding Brigatinib, the FDA will announce whether, or not, they have granted "early review " of our NDA, within the next 14 days. I say this because according to FDA rules, they have 60 days to act upon the request, which I believe was submitted on August 30th.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.